Cargando…

Eculizumab versus rituximab in generalised myasthenia gravis

OBJECTIVE: Myasthenia gravis (MG) is the most common autoimmune disorder affecting the neuromuscular junction. However, evidence shaping treatment decisions, particularly for treatment-refractory cases, is sparse. Both rituximab and eculizumab may be considered as therapeutic options for refractory...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nelke, Christopher, Schroeter, Christina B, Stascheit, Frauke, Pawlitzki, Marc, Regner-Nelke, Liesa, Huntemann, Niklas, Arat, Ercan, Öztürk, Menekse, Melzer, Nico, Mergenthaler, Philipp, Gassa, Asmae, Stetefeld, Henning, Schroeter, Michael, Berger, Benjamin, Totzeck, Andreas, Hagenacker, Tim, Schreiber, Stefanie, Vielhaber, Stefan, Hartung, Hans-Peter, Meisel, Andreas, Wiendl, Heinz, Meuth, Sven G, Ruck, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Neuromuscular
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016243/ https://www.ncbi.nlm.nih.gov/pubmed/35246490 http://dx.doi.org/10.1136/jnnp-2021-328665

Ejemplares similares

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients
por: Nelke, Christopher, et al.
Publicado: (2022)

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement
por: Nelke, Christopher, et al.
Publicado: (2023)

Enjoy Carefully: The Multifaceted Role of Vitamin E in Neuro-Nutrition
por: Regner-Nelke, Liesa, et al.
Publicado: (2021)

Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019
por: Pawlitzki, Marc, et al.
Publicado: (2022)

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
por: Imai, Tomihiro, et al.
Publicado: (2018)

Current Biomarker Strategies in Autoimmune Neuromuscular Diseases
por: Oeztuerk, Menekse, et al.
Publicado: (2023)

High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies
por: Nelke, Christopher, et al.
Publicado: (2022)

Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells
por: Schroeter, Christina B., et al.
Publicado: (2021)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade
por: Nelke, Christopher, et al.
Publicado: (2023)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection
por: Pawlitzki, Marc, et al.
Publicado: (2021)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

Neonatal Fc Receptor–Targeted Therapies in Neurology
por: Nelke, Christopher, et al.
Publicado: (2022)

Bilateral vocal cord palsy as complication of CNS tuberculosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2023)

Classifying flow cytometry data using Bayesian analysis helps to distinguish ALS patients from healthy controls
por: Räuber, Saskia, et al.
Publicado: (2023)

Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B
por: Takahashi, Toshiaki, et al.
Publicado: (2013)

Whole-genome sequencing and the clinician: a tale of two cities
por: Foley, A Reghan, et al.
Publicado: (2014)

Autosomal dominant eccentric core disease caused by a heterozygous mutation in the MYH7 gene
por: Romero, Norma B, et al.
Publicado: (2014)

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients
por: Querin, Giorgia, et al.
Publicado: (2016)

Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation?
por: Prell, Tino, et al.
Publicado: (2016)

Imaging muscle as a potential biomarker of denervation in motor neuron disease
por: Jenkins, Thomas M, et al.
Publicado: (2018)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2018)

Classifying Adverse Events Following Lower Limb Orthopaedic Surgery in Children With Cerebral Palsy: Reliability of the Modified Clavien-Dindo System
por: Zhou, Leena, et al.
Publicado: (2018)

Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy
por: Strauss, Kevin A., et al.
Publicado: (2018)

Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
por: Kaji, Ryuji, et al.
Publicado: (2019)

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
por: Diaz-Manera, Jordi, et al.
Publicado: (2018)

Differentiating lower motor neuron syndromes
por: Garg, Nidhi, et al.
Publicado: (2017)

Untargeted metabolomics yields insight into ALS disease mechanisms
por: Goutman, Stephen A, et al.
Publicado: (2020)

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019)

Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2019)

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
por: Capodivento, Giovanna, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study
por: Verboon, Christine, et al.
Publicado: (2021)

IgG(1) pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
por: Fehmi, Janev, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eio0klpd3css5gevbl81vir8qp